UBS AG’s latest price target increase for Zai Lab Ltd. signals a broader bet on the drugmaker’s strategic pivot from a China-focused licensee to a global oncology player, a move that could unlock value far beyond its current revenue streams.
"For the past three years, we started an effort to develop drugs on a global scale," Rafael Amado, Zai Lab’s Head of Global R&D, told Fierce Biotech, encapsulating the strategic shift that underpins the market’s growing optimism.
The Swiss bank reiterated its Buy rating on Zai Lab’s Hong Kong-listed shares while lifting its price target by 18% to HKD 27 from HKD 22.8. The bullish long-term view comes even as UBS analysts trimmed near-term forecasts, acknowledging competitive and pricing headwinds for the company’s established drugs in China. UBS cut its first-quarter 2026 sales forecast for the autoimmune drug VYVGART to $18 million from $22 million and for the cancer therapy Zejula to $35 million from $42 million.
At stake is whether Zai Lab can successfully transition from a business that generated $460 million in 2025 by selling partnered drugs in China to a company that develops and launches its own blockbuster therapies on the world stage. The UBS note suggests investors are increasingly willing to look past immediate challenges and price in the potential of a pipeline led by a single promising asset.
Zoci Program Holds the Key
The linchpin of Zai Lab’s global ambition is zocilurtatug pelitecan, or ‘zoci,’ an antibody-drug conjugate (ADC) targeting the protein DLL3, which is expressed in small cell lung cancer (SCLC) and other neuroendocrine tumors. The company licensed the drug from China-based MediLink Therapeutics and is positioning it as its first potential global launch.
Early data presented at the American Association for Cancer Research annual meeting showed zoci produced a 38% response rate in non-lung neuroendocrine carcinomas and, crucially, shrank brain tumors in 10 of 16 SCLC patients. The ability to penetrate the blood-brain barrier addresses a significant unmet need, as up to 70% of SCLC patients eventually develop brain metastases. A Phase 3 trial in relapsed SCLC is now underway.
A Strategic Shift Worth More Than HKD 27
The focus on zoci highlights the stark contrast between Zai Lab’s past and its future. While its portfolio of eight licensed drugs brought in $460 million last year, analysts see the potential for zoci alone to surpass that figure. Analysts at Citi, for example, model zoci’s peak sales potential around $500 million.
This strategic evolution is a capital-intensive necessity, according to company leadership. "You can't afford global development unless you have an opportunity to be in the U.S. market,” Zai Lab President and COO Josh Smiley told Fierce Biotech. By leveraging its entrenched and efficient clinical development team in China for early-stage trials before advancing to global registrational studies, Zai Lab aims to build a sustainable engine for innovation.
For investors, the UBS upgrade frames the current moment as an inflection point. The story is no longer solely about sales of Zejula or VYVGART in China but about the clinical and commercial execution of a global pipeline. While Zai Lab faces the execution risk inherent in late-stage drug development, the potential reward is a transformation into a self-sustaining biopharma company—a narrative the market is beginning to buy into.
This article is for informational purposes only and does not constitute investment advice.
